Speaker
Description
Recently targeted alpha therapy (TAT) using actinium-225 (225Ac) has been interested due to impressive clinical results. The 225Ac radioisotope decays into bismuth-209 by emitting four alpha and two beta particles with a half-life of 9.9 days, which is appropriate for medical applications. Several research groups reported that ample quantities of 225Ac could be produced via spallation of thorium-232 (232Th) with energetic protons, having less than 0.1% of 225Ac as a byproduct. In order to reduce the 227Ac/225Ac ratio, IRIS will employ the energy range of 50-70 MeV protons irradiated onto the Th target. The target has the structure of 30 mm diameter and the thickness of 5 mm ThO2 encapsulated by 0.5 mm Al foil, which securely sealed the target material. To ensure the stability and safety of thorium targets under high-power beam conditions, a packaging design for the protective Al layer of thorium targets will be adapted with accompanied by detailed mechanical and thermal analyses. Also, an evaluation of the radiation shielding for proton-irradiated thorium target will be presented. This process focuses on protecting personnel and the public by calculating dose rates around the target system and ensuring the dose rates remain below regulatory limits.
This work was supported by INNOPOLIS grant funded (RS-2025-13632970) and by National Research Foundation (NRF) grant (TOPTIER, RS-2024-00436392) by the Korea government of Ministry of Science and ICT (MSIT)
| Paper submission Plan | Yes |
|---|---|
| Best Presentation | No |
